Диссертация (1139842), страница 22
Текст из файла (страница 22)
– Т. 9. – №. 4. – С. 208.196.Pudil R., Tichy M., Andrys C. et al. Plasma interleukin-6 level isassociated with NT-proBNP level and predicts short-and long-term mortalityin patients with acute heart failure //Acta Medica (Hradec Kralove). – 2010.– Т. 53. – №. 4. – С. 225-228.197.Putten K., Jie, K. E., Broek, D. et al. Hepcidinresponse rather than resistance to exogenous erythropoietin in chronic‐25 is a m124kidney disease/chronic heart failure patients // European journal of heartfailure. – 2010. – Т. 12. – №. 9. – С.
943-950.198.Rajendiran KS, Ananthanarayanan RH, Satheesh S et al. Elevatedlevels of serum sialic acid and high-sensitivity C-reactive protein: markersof systemic inflammation in patients with chronic heart failure // Britishjournal of biomedical science. – 2014. – Т. 71. – №. 1. – С. 29-32.199.Ramey G., Deschemin J.C., Durel B. et al. Hepcidin targetsferroportin for degradation in hepatocytes // haematologica.
– 2009. –Т.95. №3.- С.501—514.200.Reichert C. O., da Cunha, J., Levy, D.et al. Hepcidin: Homeostasisand Diseases Related to Iron Metabolism //Acta haematologica. – 2017. – Т.137. – №. 4. – С. 220-236.201.Salisbury A. C., Kosiborod M. Outcomes associated with anemia inpatients with heart failure // Heart failure clinics.
– 2010. – Т. 6. – №. 3. – С.359-372.202.Sarnak M. J., Tighiouart, H., Manjunath, G. et al. Anemia as a riskfactor for cardiovascular disease in The Atherosclerosis Risk inCommunities (ARIC) study // Journal of the American College ofCardiology. – 2002.
– Т. 40. – №. 1. – С. 27-33.203.Sasu B.J., Cooke K.S., Arvedson T.L. et al. Anti-hepcidin antibodytreatment modulates iron metabolism and is effective in a mouse model ofinflammation-induced anemia // Blood. – 2010. – Т.115. - № 17. – С.3616—3624.204.Shirazi L. F., Bissett, J., Romeo, F. et al. Role of inflammation inheart failure // Current atherosclerosis reports. – 2017. – Т. 19. – №.
6. – С.27.205.Silverberg DS, Wexler D, Blum M. et al. The use of subcutaneouserythropoietin and intravenous iron for the treatment of the anemia ofsevere, resistant congestive heart failure improves cardiac and renal functionand functional cardiac class, and markedly reduces hospitalizations //125Journal of the American College of Cardiology. – 2000. – Т. 35. – №. 7. –С. 1737-1744.206.Silverberg DS, Wexler D. Iaina A. et al. Anemia, chronic renal diseaseand chronic heart failure: the cardiorenal anemia syndrome // TransfusionAlternatives in Transfusion Medicine. – 2008. – Т.
10. – №. 4. – С. 189-196.207.Silverberg D. S., Wexler D., Blum M. et al. The interaction betweenheart failure, renal failure and anemia–the cardio-renal anemia syndrome //Blood purification. – 2004. – Т. 22. – №. 3. – С. 277-284.208.Son Y. J., Kim B. H. Prevalence of anemia and its influence onhospital readmissions and emergency department visits in outpatients withheart failure // European Journal of Cardiovascular Nursing. – 2017. – Т. 16.– №. 8. – С. 687-695.209.Song S.N., Tomosugi N., Kawabata H. et al. Downregulation ofhepcidin resulting from long-term treatment with an anti-IL-6 receptorantibody (tocilizumab) improves anemia of inflammation in multicentricCastleman's disease (MCD) // Blood.
– 2010. – Т.- 116. №.18. - С. 3627—3634.210.Steinborn W., Doehner W., Anker S. D. Anemia in chronic heartfailure--frequency and prognostic impact // Clinical nephrology. – 2003. – Т.60. – С. 103-107.211.Steinborn W., Ponikowski P ., Anker S. Anemia and congestive heartfailure // Circulation.- 2003.-Т.108.- №.6.-С.412.212.Strandberg T. E., Tilvis R. S. C-reactive protein, cardiovascular riskfactors, and mortality in a prospective study in the elderly //Arteriosclerosis,thrombosis, and vascular biology.
– 2000. – Т. 20. – №. 4. – С. 1057-1060.213.Sun C.C., Vaja V., Babitt J.L. et al. Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronicdisease and anemia of inflammation //American journal of hematology. –2012. – Т. 87. – №. 4. – С. 392-400.126214.Swinkels D. W., Girelli, D., Laarakkers, C. et al. Advances inquantitative hepcidin measurements by time-of-flight mass spectrometry //PLoS One. – 2008. – Т.
3. – №. 7. – С. 2706.215.Tang WHW, Tong W, Jain A, et al. Evaluation and long-termprognosis of new-onset, transient, and persistent anemia in ambulatorypatients with chronic heart failure //Journal of the American College ofCardiology. – 2008. – Т. 51. – №. 5. – С. 569-576.216.Tang Y. D., Katz S. D. Anemia in chronic heart failure: prevalence,etiology, clinical correlates, and treatment options // Circulation. – 2006. –Т. 113. – №. 20. – С. 2454-2461.217.Tang Y. D., Katz S. D. The prevalence of anemia in chronic heartfailure and its impact on the clinical outcomes // Heart failure reviews. –2008.
– Т. 13. – №. 4. – С. 387-392.218.Tanner H, G Moschovitis, GM Kuster, et al. The prevalence of anemiain chronic heart failure // International journal of cardiology. – 2002. – Т.86. – №. 1. – С. 115-121.219.Ter Maaten J. M., Damman, K., Verhaar, M. C. et al. Connectingheart failure with preserved ejection fraction and renal dysfunction: the roleof endothelial dysfunction and inflammation // European journal of heartfailure.
– 2016. – Т. 18. – №. 6. – С. 588-598.220.Theurl I, Mattle V, Seifert M. et al. Dysregulated monocyte ironhomeostasis and erythropoietin formation in patients with anemia of chronicdisease // Blood. – 2006. – Т. 107. – №. 10. – С. 4142-4148.221.Theurl I., Schroll A., Sonnweber T. et al. Pharmacologic inhibition ofhepcidin expression reverses anemia of chronic inflammation in rats //Blood. – 2011. Т.118. - №18.- С. 4977—4984.222.Thomas C., Thomas L.
Anemia of chronic disease: pathophysiologyand laboratory diagnosis // Laboratory hematology: official publication ofthe International Society for Laboratory Hematology. – 2005. – Т. 11. – №.1. – С. 14-23.127223.Tim Goodnough L. Comin‐Colet, J., Leal‐Noval, et al.Management of anemia in patients with congestive heart failure //Americanjournal of hematology.
– 2017. – Т. 92. – №. 1. – С. 88-93.224.Ueland T. Gullestad, L., Nymo, S. H. et al. Inflammatory cytokines asbiomarkers in heart failure // Clinica Chimica Acta. – 2015. – Т. 443. – С.71-77.225.Van Breda G. F. Bongartz, L. G., Zhuang, W. et al. Cardiac hepcidinexpression associates with injury independent of iron //American journal ofnephrology. – 2016. – Т. 44.
– №. 5. – С. 368-378.226.Van D.V, Urso R, Laroche C. et al. Co‐morbiditheart failure: an analysis of the European Heart Failure Pilot Survey //European journal of heart failure. – 2014. – Т. 16. – №. 1. – С. 103-111.227.Van Der Meer P., Lok, D. J., Januzzi, J. L. et al. Adequacy ofendogenous erythropoietin levels and mortality in anaemic heart failurepatients // European heart journal. – 2008. – Т. 29. – №.
12. – С. 1510-1515.228.Van der Meer P., Voors, A. A., Lipsic, E. et al. Prognostic value ofplasma erythropoietin on mortality in patients with chronic heart failure //Journal of the American College of Cardiology. – 2004. – Т. 44. – №. 1. –С. 63-67.229.van der Putten K., Jie, K. E., van den Broek, D et al. Hepcidinmarker of the response rather than resistance to exogenous erythropoietin inchronic kidney disease/chronic heart failure patients // European journal ofheart failure. – 2010. – Т.
12. – №. 9. – С. 943-950.230.van Rhee F., Fayad L., Voorhees P. et al. Siltuximab, a novel anti–interleukin-6 monoclonal antibody, for Castleman's disease // Journal ofclinical oncology. – 2010. – Т. 28. – №. 23. – С. 3701-3708.231.Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markersand risk of heart failure in elderly subjects without prior myocardialinfarction: the Framingham Heart Study // Circulation.
– 2003. – Т. 107. –№. 11. – С. 1486-1491.‐25 is a128232.Vela D. Balance of cardiac and systemic hepcidin and its role in heartphysiology and pathology // Laboratory Investigation. – 2018. – Т. 98. – №.3. – С. 315.233.Volpe M., Tritto, C., Testa, U.et al. Blood levels of erythropoietin incongestive heart failure and correlation with clinical, hemodynamic, andhormonal profiles //American Journal of Cardiology. – 1994. – Т. 74.
– №.5. – С. 468-473.234.Von Haehling S., Gremmler, U., Krumm, M. et al. Prevalence andclinical impact of iron deficiency and anaemia among outpatients withchronic heart failure: The PrEP Registry // Clinical Research in Cardiology.– 2017. – Т. 106.
– №. 6. – С. 436-443.235.Wedel H, McMurray J, Lindberg M et al. Predictors of fatal and non ‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in HeartFailure (CORONA): incremental value of apolipoprotein A‐1, high‐‐reactive pepsensitivity Cpeptide // European journal of heart failure. – 2009. – Т. 11. – №. 3. – С.281-291.236.Weiss G., Goodnough L. T. Anemia of chronic disease //New EnglandJournal of Medicine.
– 2005. – Т. 352. – №. 10. – С. 1011-1023.237.Weiss G., Schett G. Anaemia in inflammatory rheumatic diseases //Nature Reviews Rheumatology. – 2013. – Т. 9. – №. 4. – С. 205.238.Weizer-Stern O., Adamsky K., Amariglio N. et al. Downregulation ofhepcidin and haemojuvelin expression in the hepatocyte cell‐line HepGinduced by thalassaemic sera // British journal of haematology. – 2006. – Т.135. – №. 1. – С.
129-138.239.Wel M. C., Jansen, R. W., Bakx, J. C. et al. Non‐cardiovmorbidity in elderly patients with heart failure outnumbers cardiovascularco– С. 709-715.– 2007. – Т.//9.European– №. 6-7.journal of‐morbidity129240.Wolff J. L., Starfield B., Anderson G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
